StockNews.AI
TBPH
StockNews.AI
188 days

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

1. TBPH will report Q4 2024 results on February 26, 2025. 2. Conference call will provide a business update following the earnings report. 3. The company focuses on developing treatments for COPD and MSA. 4. Ampreloxetine is a late-stage candidate for neurogenic orthostatic hypotension. 5. YUPELRI is already an FDA-approved treatment for COPD.

Earnings
+4.87%Current Return
VS
+0.14%S&P 500
$9.0402/12 06:04 AM EDTEvent Start
$9.4802/13 12:59 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports can positively influence stock performance. Previous positive earnings announcements have uplifted TBPH stock.

How important is it?

Earnings reports are crucial for investor confidence and price movement. The focus on pipeline drugs may also attract interest.

Why Short Term?

Earnings reports typically impact stock prices in the short term. Past results show significant immediate market reactions.

Related Companies

COPDMSA
, /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 28, 2025. About Theravance Biopharma Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value. For more information, please visit www.theravance.com. THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners. Contact:[email protected]650-808-4045 SOURCE Theravance Biopharma, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News